InvestorsHub Logo
Followers 19
Posts 3200
Boards Moderated 2
Alias Born 06/05/2020

Re: None

Thursday, 05/11/2023 4:21:30 PM

Thursday, May 11, 2023 4:21:30 PM

Post# of 42
With our Breakthrough Device Designation for the treatment of certain patients with squamous cell carcinoma, we look forward to swift accrual into our U.S. pivotal ReSTART trial, with the goal of bringing the Alpha DaRT closer to availability for patients as quickly as possible."

The results of the trial demonstrated that the treatment was successfully delivered to ten of ten patients, with a 100% CR observed at 12 and 24 weeks,

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRTS News